IDH1 and central nervous system cancer: The data further suggested that not all IDH1/2 wild-type lower grade gliomas are uniformly aggressive and additional markers including TERTp mutation and EGFR amplification should be examined in the clinical management of lower-grade gliomas with wild-type IDH1/2.